[Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management]

Clémence Basse; Aurelie Swalduz; Matteo Giaj Levra; Nicolas Girard; Jordi Remon; Denis Moro-Sibilot

doi:10.1016/j.bulcan.2020.04.018

[Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management]

Bull Cancer. 2020 Jul-Aug;107(7-8):779-791. doi: 10.1016/j.bulcan.2020.04.018. Epub 2020 Jun 10.

[Article in French]

Authors

Clémence Basse¹, Aurelie Swalduz², Matteo Giaj Levra³, Nicolas Girard¹, Jordi Remon⁴, Denis Moro-Sibilot⁵

Affiliations

¹ Institut du thorax Curie Montsouris, institut Curie, Paris, France.
² Centre Léon-Bérard, département d'oncologie médicale, Lyon, France.
³ CHU de Grenoble-Alpes, oncologie thoracique SHUPP, CS10217 cedex, 38043 Grenoble, France; Hospital HM Delfos, HM Hospitales, Centro Integral Oncológico Clara-Campal (HM-CIOCC), Department of Medical Oncology, Barcelona, Espagne; Université Grenoble-Alpes, Institute for Advanced Biosciences, Inserm U1209 CNRS UMR5309, Grenoble, France.
⁴ Hospital HM Delfos, HM Hospitales, Centro Integral Oncológico Clara-Campal (HM-CIOCC), Department of Medical Oncology, Barcelona, Espagne.
⁵ CHU de Grenoble-Alpes, oncologie thoracique SHUPP, CS10217 cedex, 38043 Grenoble, France. Electronic address: DMoro.pneumo@chu-grenoble.fr.

PMID: 32532420
DOI: 10.1016/j.bulcan.2020.04.018

Abstract

Immunotherapy alone or in combination with chemotherapy is now an integral part of the treatment of metastatic NSCLC. This treatment is transforming the management of these cancers, with 20-30% of patients achieving long survival. However, disease progression under treatment is still the rule for the majority of patients, raising problems both in understanding its mechanisms and in subsequent appropriate management. This study examines current therapeutic options and proposes solutions to circumvent resistance to immunotherapy. The mechanisms of resistance to these treatments is also analysed.

Keywords: Cancers bronchiques; Chemotherapy; Chimiothérapie; Immunotherapy; Immunothérapie; Lung cancer; Mechanisms of resistance; Mécanismes de résistance.

Publication types

Review

MeSH terms

Anaplastic Lymphoma Kinase / genetics
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / mortality
Carcinoma, Non-Small-Cell Lung / therapy*
Clinical Trials, Phase III as Topic
Combined Modality Therapy / methods
Disease Progression
Drug Resistance, Neoplasm / physiology
Genes, erbB-1
Humans
Immunotherapy / methods*
Immunotherapy, Adoptive / methods
Lung Neoplasms / genetics
Lung Neoplasms / mortality
Lung Neoplasms / therapy*
Mutation
Receptors, Chimeric Antigen / therapeutic use
Translocation, Genetic

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Receptors, Chimeric Antigen
pembrolizumab
ALK protein, human
Anaplastic Lymphoma Kinase